Kapelios Chris J, Nanas John N, Malliaras Konstantinos
3rd Department of Cardiology, University of Athens School of Medicine, 67 Mikras Asias Street, 11 527, Athens, Greece.
Future Cardiol. 2016 Jan;12(1):87-100. doi: 10.2217/fca.15.72. Epub 2015 Dec 21.
Early-phase clinical testing of autologous cardiosphere-derived cells (CDCs) has yielded intriguing results, consistent with therapeutic myocardial regeneration. However, autologous therapy is associated with significant technical, timing, economic and logistic constraints, prompting researchers to explore the potential of allogeneic CDC therapy. CDCs exhibit a favorable immunologic antigenic profile and are hypoimmunogenic in vitro. Preclinical studies in immunologically mismatched animals demonstrate that allogeneic CDC transplantation without immunosuppression is safe and produces sustained functional and structural benefits through stimulation of endogenous regenerative pathways. Currently, allogeneic human CDCs are being tested clinically in the ALLSTAR and DYNAMIC trials. Potential establishment of clinical safety and efficacy of allogeneic CDCs combined with generation of highly standardized, 'off-the-shelf' allogeneic cellular products would facilitate broad clinical adoption of cell therapy.
自体心脏球衍生细胞（CDC）的早期临床试验已产生了有趣的结果，这与治疗性心肌再生一致。然而，自体疗法存在重大的技术、时间、经济和后勤限制，促使研究人员探索同种异体CDC疗法的潜力。CDC表现出良好的免疫抗原谱，并且在体外具有低免疫原性。在免疫不匹配动物中的临床前研究表明，不进行免疫抑制的同种异体CDC移植是安全的，并且通过刺激内源性再生途径可产生持续的功能和结构益处。目前，同种异体人CDC正在ALLSTAR和DYNAMIC试验中进行临床测试。同种异体CDC临床安全性和有效性的潜在确立，以及高度标准化的“现成”同种异体细胞产品的产生，将促进细胞疗法在临床上的广泛应用。
